UNSW Sydney’s Centre for Molecular Oncology will partner with not-for-profit cancer genomics leader Omico to deliver the national precision oncology program PrOSPeCT.
A new modelling study led by UNSW predicts demand for cancer surgery will rise by 52 per cent within two decades, with low-income countries bearing the greatest burden.
Children fighting a life-threatening form of cancer could be treated with a revolutionary anti-cancer therapy as early as next year, following the formation of a research alliance to fast-track development of a drug pioneered by UNSW researchers.
